Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2020

View Archived Issues

OyaGen to develop OYA-1 for the treatment of coronaviruses

Denali studies DNL-343 in healthy volunteers in new phase I trial

Researchers present phase II data for tafoxiparin in women in labor

Aclaris initiates phase IIa study of ATI-450 with methotrexate for moderate to severe RA

Chlorotoxin-CAR T cells specifically targeting glioblastomas shows preclinical antitumor activity

Poseida Therapeutics initiates phase I study of P-PSMA-101 CAR-T cells

Patient enrollment ongoing in phase I study of CS-3002

Phase IIb ARISE study of padsevonil does not reach statistical significance for primary endpoints

Anti-POTEF autoantibodies as new biomarker in primary ovarian insufficiency

NPSR1 as a novel nonhormonal target in endometriosis

First-in-human data for (R,R)-penehyclidine fumarate

New approach to cancer immunotherapy identified

FDA clears IND for phase I/II trial of Adaptive Phage Therapeutics' PhageBank

Researchers develop murine model of CMV infection in pregnancy

See in 3D

PharmaMar reports promising in vitro study results with Aplidin against coronavirus HCoV-229E

University of Edinburgh discloses new cyclophilin inhibitors

New glutaminyl cyclase inhibitors patented by Academia Sinica, NHRI

Daewoong Pharmaceutical describes dual BTK/ITK inhibitors

Merck KGaA discovers Bruton tyrosine kinase inhibitors

New pantetheinase inhibitors presented by Boehringer Ingelheim

Janssen collaborates with Beth Israel Deaconess on preventive vaccine candidate for COVID-19

Algernon to seek funding from COVID-19 Therapeutic Accelerator program for repurposed drug

Preclinical data show PAT-DX1 crosses blood-brain barrier via ENT2 pathway

Japanese approval for new Ozempic SD subcutaneous injection formulation

Kevzara enters global clinical program for use in severe COVID-19 infection

Trial of darunavir/cobicistat and hydroxychloroquine to reduce transmission of SARS-CoV-2 begins